NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018
2018; National Comprehensive Cancer; Volume: 16; Issue: 12 Linguagem: Inglês
10.6004/jnccn.2018.0089
ISSN1540-1413
AutoresRobert I. Haddad, Christian Nasr, Lindsay A. Bischoff, Naifa L. Busaidy, David R. Byrd, Glenda G. Callender, Paxton V. Dickson, Quan‐Yang Duh, Hormoz Ehya, Whitney Goldner, Megan R. Haymart, Carl K. Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick Lamonica, Bryan McIver, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Rebecca S. Sippel, Robert C. Smallridge, Cord Sturgeon, Thomas J. Wang, Lori J. Wirth, Richard J. Wong, Alyse Johnson-Chilla, K Hoffmann, Lisa A. Gurski,
Tópico(s)Thyroid Cancer Diagnosis and Treatment
ResumoThe NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E-mutated anaplastic thyroid carcinoma.
Referência(s)